Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
8233 ARTÍCULOS , VIENDO DEL 721 AL 735
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Høilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B.
Ageing Res Rev. 2024 Aug;99:102348. doi: 10.1016/j.arr.2024.102348. Epub 2024 Jun 1.
Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy
Sai Varshini M, Aishwarya Reddy R, Thaggikuppe Krishnamurthy P.
J Drug Target. 2024 Sep;32(8):909-917. doi: 10.1080/1061186X.2024.2365263. Epub 2024 Jun 11.
Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges
Iqbal I, Saqib F, Mubarak Z, Latif MF, Wahid M, Nasir B, Shahzad H, Sharifi-Rad J, Mubarak MS.
Eur J Med Res. 2024 Jun 8;29(1):313. doi: 10.1186/s40001-024-01915-3.
Dong Q, Fu H, Jiang H.
Biomed Pharmacother. 2024 Jul;176:116880. doi: 10.1016/j.biopha.2024.116880. Epub 2024 Jun 7.
The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease
Balusu S, De Strooper B.
Acta Neuropathol. 2024 Jun 9;147(1):96. doi: 10.1007/s00401-024-02747-5.
Multi-target drugs for Alzheimer's disease
Turgutalp B, Kizil C.
Trends Pharmacol Sci. 2024 Jul;45(7):628-638. doi: 10.1016/j.tips.2024.05.005. Epub 2024 Jun 9.
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross AL, Shade D, Lanctôt KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB.
Int J Geriatr Psychiatry. 2024 Jun;39(6):e6108. doi: 10.1002/gps.6108.
Chen X, Walton K, Brodaty H, Chalton K.
J Alzheimers Dis. 2024;101(s1):S479-S501. doi: 10.3233/JAD-231222.
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler DA.
J Alzheimers Dis. 2024;100(2):379-411. doi: 10.3233/JAD-240212.
Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis
Menegaz de Almeida A, Leite M, Lopes LM, Gomes Lima P, Siegloch Barros ML, Rocha Pinheiro S, Andrade Í, Viana P, Morbach V, Marinheiro G, de Oliveira R, Pinheiro AC.
Expert Rev Neurother. 2024 Sep;24(9):929-936. doi: 10.1080/14737175.2024.2367016. Epub 2024 Jun 16.
Aggregation Mechanisms and Molecular Structures of Amyloid-β in Alzheimer's Disease
Niu Z, Gui X, Feng S, Reif B.
Chemistry. 2024 Aug 27;30(48):e202400277. doi: 10.1002/chem.202400277. Epub 2024 Aug 2.
A Comprehensive Analytical Review of Polyphenols: Evaluating Neuroprotection in Alzheimer's Disease
Vicente-Zurdo D, Gómez-Mejía E, Rosales-Conrado N, León-González ME.
Int J Mol Sci. 2024 May 28;25(11):5906. doi: 10.3390/ijms25115906.
Special Issue "Pathophysiology and Treatment of Alzheimer's Disease"
Fessel J.
Int J Mol Sci. 2024 May 30;25(11):6015. doi: 10.3390/ijms25116015.
CDK5 as a therapeutic tool for the treatment of Alzheimer's disease: A review
Garemilla S, Kumari R, Kumar R.
Eur J Pharmacol. 2024 Sep 5;978:176760. doi: 10.1016/j.ejphar.2024.176760. Epub 2024 Jun 18.
Shastri D, Raj V, Lee S.
Ageing Res Rev. 2024 Aug;99:102379. doi: 10.1016/j.arr.2024.102379. Epub 2024 Jun 18.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.